Alnylam Q1 net product rev $365M (+32% YoY); net loss narrows to $0.52/share

ALNYLAM PHARMACEUTICALS, INC.

2024-Q1 EPS reported -$0.52 revenue$494,333,000

Net product revenue $365M, up 32% YoY; TTR franchise $264M (+29%), Rare $101M (+40%).
GAAP net loss $65.9M ($0.52 per share) vs $174.1M ($1.40) in Q1 2023.
2024 guidance reiterated: combined net product revenue $1.4B–$1.5B.
Zilebesiran: positive KARDIA-2 results; KARDIA-3 initiated, triggering $65M Roche milestone.
HELIOS-B Phase 3 topline results for vutrisiran on track for late June/early July.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ALNYLAM PHARMACEUTICALS, INC. reported the quarter ended March 31, 2024 results: revenue $365 million, net income GAAP Net loss $65,935 (in thousands), EPS GAAP Net loss per common share - basic and diluted $0.52. Guidance reaffirmed.

Period: the quarter ended March 31, 2024
Revenue: $365 million
Net income: GAAP Net loss $65,935 (in thousands)
EPS: GAAP Net loss per common share - basic and diluted $0.52
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity − Achieved First Quarter 2024 Global Net Product Revenues of $365 Million

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001178670-24-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.